Table 1.
Baseline features of study population.
| Tocilizumab (N = 74) | Standard of care (N = 148) | p | ||
|---|---|---|---|---|
| Age (years), median [IQR] | 59 [51–71] | 59 [52–70] | 0.865 | |
| Male sex,% | 82.4 | 81.1 | 0.807 | |
| Ethnicity,% | Caucasian | 78.4 | 84.5 | 0.267 |
| MENA Region | 9.5 | 3.4 | ||
| South American | 10.8 | 7.4 | ||
| Asian | 1.3 | 3.4 | ||
| Black African | – | 1.3 | ||
| Critical disease,% | 79.7 | 69.6 | 0.109 | |
| P/F (mmHg), median [IQR] | Severe disease | 229 [183–276] | 295 [222–375] | 0.009 |
| Critical disease | 136 [93–197] | 159 [93–246] | 0.459 | |
| Charlson Comorbidity Index, median [IQR] | 2 [1–3] | 2 [1–4] | 0.631 | |
| Time from symptoms onset to hospital admittance (days), median [IQR] | 7 [5–10] | 6 [4–8] | 0.080 | |
| Antiviral treatment,% | LPV/rtv | 75.7 | 85.1 | 0.084 |
| Hydroxychloroquine | 90.5 | 89.9 | 0.644 | |
| Remdesivir | 9.5 | 8.1 | 0.689 | |
IQR: interquartile range; MENA: Middle East and North Africa; P/F: Horowitz Index, defined as the ratio of partial arterial oxygen pressure and fraction of oxygen in the inhaled air; LPV/rtv: lopinavir co-formulated with ritonavir.